Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Fulvestrant in ER+/PR+ Cancers with PI3K/PTEN Alterations
NCT05082025Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib in endometrial cancer (EC), ovarian cancer, breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2022; status: terminated.
02
Drugs
copanlisib
03
Conditions
endometrial cancer (EC)ovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT05082025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082025.